Importer of Controlled Substances Application: Cardinal Health, 35664 [2020-12625]

Download as PDF 35664 Federal Register / Vol. 85, No. 113 / Thursday, June 11, 2020 / Notices regarding filing should contact the Secretary (202–205–2000). Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this Investigation may be disclosed to and used: (i) By the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personnel,1 solely for cybersecurity purposes. All non-confidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS. The Commission vote for these determinations took place on June 5, 2020. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). [FR Doc. C1–2020–10601 Filed 6–10–20; 8:45 am] Drug Enforcement Administration [Docket No. DEA–663] Importer of Controlled Substances Application: Cardinal Health Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 13, 2020. Such persons may also file a written request for a hearing on the application on or before July 13, 2020. DATES: ADDRESSES: Controlled substance Drug code Schedule Correction In notice document 2020–10601, appearing on pages 29741 through 1 All contract personnel will sign appropriate nondisclosure agreements. VerDate Sep<11>2014 17:33 Jun 10, 2020 Jkt 250001 Agency Information Collection Activities; Proposed eCollection; eComments Requested; Extension Without Change of Previously Approved Collection OJP Solicitation Template Office of Justice Programs, Department of Justice. ACTION: 60-Day notice. Notice of application. In accordance with 21 CFR 1301.34(a), this is notice that on June 1, 2020, Cardinal Health, 15 Ingram Boulevard, La Vergne, Tennessee 37086–3630, applied to be registered as an importer of the following basic class(es) of controlled substance: Bulk Manufacturer of Controlled Substances Application: SpecGx LLC BILLING CODE 4410–09–P AGENCY: ACTION: SUPPLEMENTARY INFORMATION: [Docket No. DEA–610] [FR Doc. 2020–12625 Filed 6–10–20; 8:45 am] [OMB Number 1121–0329] DEPARTMENT OF JUSTICE BILLING CODE 7020–02–P Drug Enforcement Administration William T. McDermott, Assistant Administrator. DEPARTMENT OF JUSTICE [FR Doc. 2020–12594 Filed 6–10–20; 8:45 am] DEPARTMENT OF JUSTICE registrants for the purpose of medical use only. BILLING CODE 1300–01–D Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. By order of the Commission. Issued: June 5, 2020. Lisa Barton, Secretary to the Commission. jbell on DSKJLSW7X2PROD with NOTICES 29742 in the issue of Monday, May 18, 2020 make the following correction. On page 29741, in the third column, in the DATES section, on the last line, ‘‘July 17, 2025’’ should read ‘‘July 17, 2020’’. Secobarbitol .................. 2315 II The company plans to import the above controlled substance in finished dosage form for distribution to licensed PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 The Department of Justice (DOJ), Office of Justice Programs (OJP), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. DATES: Comments are encouraged and will be accepted for 60 days until August 10, 2020. FOR FURTHER INFORMATION CONTACT: If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Jennifer Yeh, (202) 616–9135, Office of Audit, Assessment, and Management, Office of Justice Programs, U.S. Department of Justice, 810 Seventh Street NW, Washington, DC 20531 or Jennifer.Yeh2@usdoj.gov. SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Office of Justice Programs, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Evaluate whether and if so how the quality, utility, and clarity of the SUMMARY: E:\FR\FM\11JNN1.SGM 11JNN1

Agencies

[Federal Register Volume 85, Number 113 (Thursday, June 11, 2020)]
[Notices]
[Page 35664]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-12625]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-663]


Importer of Controlled Substances Application: Cardinal Health

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before July 13, 2020. 
Such persons may also file a written request for a hearing on the 
application on or before July 13, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for a hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on June 1, 2020, Cardinal Health, 15 Ingram Boulevard, 
La Vergne, Tennessee 37086-3630, applied to be registered as an 
importer of the following basic class(es) of controlled substance:

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Secobarbitol...........................     2315  II
------------------------------------------------------------------------

    The company plans to import the above controlled substance in 
finished dosage form for distribution to licensed registrants for the 
purpose of medical use only.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-12625 Filed 6-10-20; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.